Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer: (IDENTIFY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03548688|
Recruitment Status : Recruiting
First Posted : June 7, 2018
Last Update Posted : June 7, 2018
Bladder cancer is common in the UK and can kill. A common sign of bladder cancer is blood in the urine (haematuria).
GPs will refer to a specialist (Urologist) for further investigation of haematuria if they suspect cancer.
Hospitals often have a 'blanket' approach for investigating patients with haematuria. IDENTIFY will collect data on patients having these tests across the UK and internationally, looking at any trends with an aim to create a personalised diagnostic approach for each patient. The data will give patients the ability to make informed decisions, as well as reducing unnecessary and potentially harmful tests.
|Condition or disease|
IDENTIFY aims to be the largest contemporary study providing data on the utility of the current diagnostic pathway for bladder and upper urinary tract cancer in patients presenting with haematuria.
It also aims to provide a contemporary evaluation of current urological practices and assessment of the prevalence of urinary tract cancers (bladder cancer, upper tract cancer, renal cancer) in patients with haematuria. This will allow us to recommend changes in cancer diagnosis pathways that may reduce the number of invasive procedures, reduce waste of resources and optimize use of the most appropriate tests. This will mean resources are spent effectively, allowing for early diagnosis and faster treatment pathways.
An evaluation of the patient factors that predict urinary tract cancer, particularly high-risk disease, may allow clinicians to better recognise groups of patients that will benefit from invasive investigations and are more likely to benefit from prompt diagnosis and treatment. Upper tract urinary cancer is quite rare and difficult to diagnose. It requires a large patient cohort such as the IDENTIFY study in order to recognise associations with the diagnosis of this disease and optimize the way we diagnose it.
Shared-decision making is extremely important in patients presenting with haematuria and the outcomes of IDENTIFY will allow a more personalized approach to the diagnosis of urinary tract cancer. For example, rather than a blanket approach in which all patients undergo flexible cystoscopy and one or more imaging tests, we will generate data that could offer patients information on the likelihood of a flexible cystoscopy or other test finding cancer for them, given their personal characteristics.
IDENTIFY results are also hoped to help inform national and international guidelines on referral for haematuria.
|Study Type :||Observational|
|Estimated Enrollment :||5000 participants|
|Official Title:||Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer: A Multicentre Analysis|
|Actual Study Start Date :||December 14, 2017|
|Estimated Primary Completion Date :||October 31, 2018|
|Estimated Study Completion Date :||December 14, 2018|
- Prevalence [ Time Frame: 12 months ]Determine the prevalence of urological cancers in patients presenting to secondary care with haematuria
- Specific prevalence [ Time Frame: 12 months ]Determine the difference in prevalence of urological cancer in those undergoing flexible cystoscopy with visible haematuria, non-visible haematuria and without haematuria
- Diagnostic strategies [ Time Frame: 12 months ]Describe the current practices in urothelial cancer diagnosis across a range of different healthcare settings in secondary care (district general vs university teaching hospital) with regards to percentage of ultrasound, CT and other imaging modality used for visible and non visible haematuria.
- Diagnostic performance of imaging [ Time Frame: 12 months ]Determine the diagnostic performance of US, CT, urine cytology and flexible cystoscopy in patients presenting with haematuria in the diagnosis of bladder cancer, using sensitivity, specificity, positive and negative predictive value.
- Associated factors [ Time Frame: 12 months ]Perform a multivariable analysis to determine factors associated with the diagnosis of bladder cancer and upper urinary tract cancer in patients presenting with haematuria
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03548688
|London, United Kingdom|
|Contact: Sinan Khadhouri 01382660111 ext #4042 email@example.com|